Gregory LaRosa, PhD, is Vice President, and Chief Scientific Officer of Pfizer’s Rare Disease Research Unit. Before Critical Therapeutics, Dr. LaRosa served as Senior Director of Immunopharmacology at Millennium Pharmaceuticals, Inc., from 1999 to 2003, where his work was focused on several inflammation drug discovery projects targeting chemokine receptors and kinases. His group delivered three new Development Candidates that entered clinical trials. From September 1994 to December 1999, Dr. LaRosa served in several senior research positions at LeukoSite, Inc., a biotechnology company focused on chemokines, adhesion proteins and inflammation drug discovery. From 1988 to September 1994, Dr. LaRosa held several research posts at Repligen, Corp., a biotechnology company in the Boston area. He has over 23 years of experience in rare disease and inflammation drug discovery and development.

Gregory LaRosa has broad interests in the development of novel anti-inflammatory, peripherally acting, compounds that target alpha-7, and demonstrated efficacy in animal models of inflammatory and allergic disease and discovery and characterization of mAbs to HMGB1, a novel target for the treatment of very severe life-threatening inflammation.